Halozyme Therapeutics (NASDAQ:HALO) Stock: Insider Helen Torley Sells 20,000 Shares

Key Points

  • Halozyme CEO Helen Torley sold 20,000 shares for $1.97 million at an average price of $98.38 under a pre-arranged Rule 10b5-1 plan. She retained 767,780 shares after the sale.
  • Halozyme reported quarterly EPS of $2.39, beating estimates of $2.30, while revenue rose 39.1% year over year to $492.97 million.
  • Analysts’ consensus rating was Hold, with an average price target of $108.18; shares opened at $96.50 after the stock had recently traded down 3.8%.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the company's stock in a transaction on Monday, November 16th. The stock was sold at an average price of $98.38, for a total value of $1,967,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company's stock, valued at $75,534,196.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

  • On Friday, November 13th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $100.38, for a total value of $2,007,600.00.
  • On Tuesday, October 6th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $109.58, for a total value of $2,191,600.00.
  • On Thursday, October 8th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.40, for a total value of $2,188,000.00.
  • On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00.
  • On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00.
  • On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00.

Halozyme Therapeutics Trading Down 3.8%




Shares of NASDAQ:HALO opened at $96.50 on Tuesday. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $134.00. The company has a market cap of $11.00 billion, a PE ratio of 18.07, a price-to-earnings-growth ratio of 0.38 and a beta of 0.92. The stock has a 50 day moving average of $114.29 and a 200 day moving average of $85.63. The company has a current ratio of 3.88, a quick ratio of 3.60 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.09. The business had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The company's revenue was up 39.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.72 earnings per share. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 8.34 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on HALO. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the company a "neutral" rating in a research note on Tuesday, November 3rd. Wall Street Zen cut Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, November 7th. HC Wainwright boosted their price objective on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a "buy" rating in a research report on Wednesday, October 7th. Morgan Stanley lowered Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and upped their price objective for the stock from $105.00 to $109.00 in a research note on Wednesday, November 11th. Finally, Benchmark reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $108.18.

View Our Latest Report on HALO

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE purchased a new position in shares of Halozyme Therapeutics in the second quarter worth $214,504,000. William Blair Investment Management LLC purchased a new position in Halozyme Therapeutics during the second quarter valued at $196,540,000. Jupiter Topco LLC purchased a new position in Halozyme Therapeutics during the second quarter valued at $105,570,000. Caisse de depot et placement du Quebec bought a new stake in Halozyme Therapeutics in the 2nd quarter valued at $83,940,000. Finally, Congress Asset Management Co. increased its holdings in Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company's stock valued at $251,890,000 after acquiring an additional 1,052,509 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Featured Stories

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Halozyme Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Halozyme Therapeutics and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles